Wells Fargo initiated coverage on Alumis with a new price target
$ALMS
Biotechnology: Pharmaceutical Preparations
Health Care
Wells Fargo initiated coverage of Alumis with a rating of Overweight and set a new price target of $17.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/25/2025 | $17.00 | Overweight | Wells Fargo |
| 6/10/2025 | $18.00 | Buy | Guggenheim |
| 1/30/2025 | $32.00 | Outperform | Oppenheimer |
| 10/31/2024 | $25.00 | Outperform | Robert W. Baird |
| 10/17/2024 | $30.00 | Buy | H.C. Wainwright |
| 7/23/2024 | Overweight | Cantor Fitzgerald | |
| 7/23/2024 | $29.00 | Outperform | Leerink Partners |
| 7/23/2024 | $32.00 | Buy | Guggenheim |
4 - ALUMIS INC. (0001847367) (Issuer)
3 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
S-3 - ALUMIS INC. (0001847367) (Filer)
8-K/A - ALUMIS INC. (0001847367) (Filer)
DEFA14A - ALUMIS INC. (0001847367) (Filer)
-Topline Readout Expected in Q3 2026- SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the completion of patient enrollment in its global LUMUS Phase 2b trial of ESK-001, a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor, for the treatment of systemic lupus erythematosus (SLE), the most common form of lupus. "Completion of enrollment in our global LUMUS Phase 2b trial for SLE marks a significant milestone for Alumis, and importantly, for the lupus community," said Martin Babler, Presiden
SOUTH SAN FRANCISCO, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary. Sanam most recently served as Senior Vice President, Legal of Alumis. In her new role, she will lead all legal and compliance functions, including corporate governance, intellectual property, and strategic advisory on key decisions and transactions. Sanam succeeds Sara Klein, following her retirement from the company. "We're thrilled to elevate Sanam to the role of Chief Legal Officer," s
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will present at the Jefferies Global Healthcare Conference on June 4, 2025 at 3:10 p.m. ET. A live webcast will be available on the Alumis website in the "Investors" section under the "Events" page. A replay of the conference webcast will be archived on the company's website for 90 days. About Alumis Alumis is a late-stage biopharma company developing next-generation targeted therapies with the pot
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
4 - ALUMIS INC. (0001847367) (Issuer)
Wells Fargo initiated coverage of Alumis with a rating of Overweight and set a new price target of $17.00
Guggenheim resumed coverage of Alumis with a rating of Buy and set a new price target of $18.00
Oppenheimer initiated coverage of Alumis with a rating of Outperform and set a new price target of $32.00
Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN's lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis Combined company wi
SC 13D - ALUMIS INC. (0001847367) (Subject)
SC 13G - ALUMIS INC. (0001847367) (Subject)
SC 13D - ALUMIS INC. (0001847367) (Subject)